Treatment of breast cancer with adriamycin hydrochloride-loaded liquid fluorocarbon liposomes
10.13929/j.1003-3289.201812144
- Author:
Lin SU
1
Author Information
1. Department of Ultrasonography, The University of Hong Kong-Shenzhen Hospital
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Liposomes;
Liquid fluorocarbon;
Ultrasonography
- From:
Chinese Journal of Medical Imaging Technology
2019;35(11):1627-1631
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To prepare the liposomes carrying doxorubicin hydrochloride (DOX) and liquid fluorocarbon (PFH) in liquid form based liposomes (Lip-PFH-DOX), and to investigate the Lip-PFH-DOX nanoparticle enhanced ultrasound imaging and its therapeutic effect on human breast cancer MAD-MB-231 cells. Methods: Lip-PFH-DOX nanoparticles were prepared by using biocompatible phospholipid mixture as film-forming material and lipophilic DOX as additive. The morphology, particle size, potential and encapsulation efficiency of Lip-PFH-DOX nanoparticles were tested. Low intensity focused ultrasound was used to induce phase transition and rupture of nanoparticles. High performance liquid chromatography was used to detect drug release at different time points. The cytotoxic effect of the nanoparticles on human breast cancer MDA-MB-231 cells was detected and the apoptosis was observed. A nude mouse breast cancer mda-mb-231 model was established, and an appropriate amount of nanoparticles were injected into the tail vein to observe the enhanced ultrasound at the tumor site. Results: The liposomes loaded with DOX and PFH were successfully prepared. The particle size was (340.81±68.54)nm, the potential was (-17.72±7.66)mV, and the drug encapsulation rate was (86.80±2.55)%. Under transmission electron microscopy, the drug was successfully encapsulated in the liposomes. Under light microscopy, the liposomes were uniform in size, and the phase transition was occured. In vitro, the release rate of DOX of Lip-PFH-DOX reached 40.05±3.22 at 48 h. After 48 h, when the concentration was 100 μg/ml of Lip-PFH-DOX, the survival rate decreased to 45.00%. Lip-PFH-DOX and the nanoparticles can significantly enhance ultrasound development in vivo after low intensity ultrasound irradiation. Conclusion: The nanoparticles of DOX and PFH was successfully prepared, which can achieve ultrasound development in vivo and in vitro, and DOX can kill MAD-MB-231 cells.
